Cell lines are used in several biological processes and have many uses in research pertaining to cell biology, biochemistry, cancer diagnostics, molecular biology and drug discovery. They offer several advantages such as cost effective, ease in use, and also provide pure cell population which is essential since it provides reproducible results and consistent sample. Various factors influence the global cell lines market. Some factors which have a direct positive impact on the cell lines market include, the extensive use of cell lines in drug discovery, development new technologies have resulted in expanding the uses of cell lines to identify and treat various ailments, cell lines being extensively used to treat cancer as the rate of cancer is growing in both developed and emerging economies, and the increased investment in research and development has boosted the growth of the cell lines market.
Cell lines are primarily used to study biologics. A cell line is a permanently established cell culture which proliferates indefinitely given fresh medium and space. A cell culture is developed from a single cell and hence consists of an unchanging genetic makeup. There are different types of cell lines which have their origin from different cell types such as hela cells, HEK 293 cells, vero cells, 3T3 cells etc. Cell lines are also used in molecular biology and cancer treatment.
According to Fact.MR’s research report on the global cell lines market, the market is anticipated to show a moderate growth rate during the forecasted period of 2017-2022 and expected to reflect a value of more than US$ 140 Mn.
North America the Most Lucrative Region
The North America region is the most attractive region for the cell lines market and this trend is expected to grow during the period of forecast. North America also possess high market attractiveness index and is expected to grow at a CAGR of 3.3% during the period of forecast of 2017 to 2022. The main reason for this region being a lucrative region for cell lines market is the investment done in the research and development. Moreover, the region is also characterized by a high technological background, and this elevates new paradigms for cell line development in the region and hence the market.
Cancer Cell Lines Show Dominance During the Period of Forecast
The cancer cell lines segment by product type reflects higher market share by revenue as of 2017 and this trend is expected to grow to retain this segment’s domination over other segments during the forecast period. Following this, the immunotherapy cell lines segment shows a comparatively high market revenue share than other segments present in the product type category. However, ion channel cell lines segment is anticipated to grow at a higher growth rate than other product segments to register a CAGR of 3.8% during the period of forecast of 2017 to 2022.
Browse More Information about this Report @ https://www.factmr.com/report/180/cell-lines-market
Basic Research Shows higher Strength, Drug Discovery and Development Shows Speed
The basic research segment by application is expected to dominate the global cell lines market by application and reflects a market share of 58.7% in 2017 and is expected to grow even further by the end of 2022. However, the drug discovery and development segment might give a tough competition to basic research as it grows at a higher rate and might be able to reach a higher market share value by the end of 2022. The drug discovery and development segment is also expected to experience a high gain in the BPs by the end of 2022.
Contract Research Organizations (CRO) Segment and Biopharmaceutical Companies Segment to Fare Almost Equally
The contract research organizations (CRO) segment is expected to grow at a higher rate during the period of forecast to register a CAGR of 3.7% whereas the biopharmaceutical companies segment is anticipated to grow at a similar yet slower (a shade slower) than the CRO segment. However, the biopharmaceutical companies segment experiences higher market share by revenue than the CRO segment. The academic and research institutes segment reflects the highest market share by revenue in 2017 and dominates the market.
Competition Tracking
The report also profiles companies that are expected to remain active in the expansion of the global cell lines market through 2022, which include Thermo Fisher Scientific, Inc., American Type Culture Collection Inc., Corning Incorporated, Lonza Group Ltd., Sartorius AG, Selexis SA, WuXi AppTec Co., Ltd., Sigma-Aldrich Corporation, General Electric Company and Abzena plc.
Cell lines are primarily used to study biologics. A cell line is a permanently established cell culture which proliferates indefinitely given fresh medium and space. A cell culture is developed from a single cell and hence consists of an unchanging genetic makeup. There are different types of cell lines which have their origin from different cell types such as hela cells, HEK 293 cells, vero cells, 3T3 cells etc. Cell lines are also used in molecular biology and cancer treatment.
According to Fact.MR’s research report on the global cell lines market, the market is anticipated to show a moderate growth rate during the forecasted period of 2017-2022 and expected to reflect a value of more than US$ 140 Mn.
North America the Most Lucrative Region
The North America region is the most attractive region for the cell lines market and this trend is expected to grow during the period of forecast. North America also possess high market attractiveness index and is expected to grow at a CAGR of 3.3% during the period of forecast of 2017 to 2022. The main reason for this region being a lucrative region for cell lines market is the investment done in the research and development. Moreover, the region is also characterized by a high technological background, and this elevates new paradigms for cell line development in the region and hence the market.
Cancer Cell Lines Show Dominance During the Period of Forecast
The cancer cell lines segment by product type reflects higher market share by revenue as of 2017 and this trend is expected to grow to retain this segment’s domination over other segments during the forecast period. Following this, the immunotherapy cell lines segment shows a comparatively high market revenue share than other segments present in the product type category. However, ion channel cell lines segment is anticipated to grow at a higher growth rate than other product segments to register a CAGR of 3.8% during the period of forecast of 2017 to 2022.
Browse More Information about this Report @ https://www.factmr.com/report/180/cell-lines-market
Basic Research Shows higher Strength, Drug Discovery and Development Shows Speed
The basic research segment by application is expected to dominate the global cell lines market by application and reflects a market share of 58.7% in 2017 and is expected to grow even further by the end of 2022. However, the drug discovery and development segment might give a tough competition to basic research as it grows at a higher rate and might be able to reach a higher market share value by the end of 2022. The drug discovery and development segment is also expected to experience a high gain in the BPs by the end of 2022.
Contract Research Organizations (CRO) Segment and Biopharmaceutical Companies Segment to Fare Almost Equally
The contract research organizations (CRO) segment is expected to grow at a higher rate during the period of forecast to register a CAGR of 3.7% whereas the biopharmaceutical companies segment is anticipated to grow at a similar yet slower (a shade slower) than the CRO segment. However, the biopharmaceutical companies segment experiences higher market share by revenue than the CRO segment. The academic and research institutes segment reflects the highest market share by revenue in 2017 and dominates the market.
Competition Tracking
The report also profiles companies that are expected to remain active in the expansion of the global cell lines market through 2022, which include Thermo Fisher Scientific, Inc., American Type Culture Collection Inc., Corning Incorporated, Lonza Group Ltd., Sartorius AG, Selexis SA, WuXi AppTec Co., Ltd., Sigma-Aldrich Corporation, General Electric Company and Abzena plc.
Comments
Post a Comment